Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 for chronic rhinosinusitis with nasal polyps long-term treatment
CTR20212128Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of stapokibart in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Keymed Biosciences. Primary endpoint: Long-term safety of CM310 in CRSwNP subjects. Started Sep 2021; status: completed.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20212128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212128.